Publications
Subramanian IV, Ghebre R, Ramakrishnan S. Adeno-associated virus mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Therapy 2005;12:30-38.
Argenta PA, Ghebre R, Dusenbery KE, Chen MD, Judson PL, Downs LS Jr, Carson LF. Radiation therapy with concomitant and adjuvant cisplatin and paclitaxel in high-risk cervical cancer: long-term follow-up. Eur J Gynaecol Oncol.2006; 27:231-235.
Chura JC, Marushin R, Boyd A, Ghebre R, Geller MA, Argenta PA. Multimodal therapy improves survival in patients with CNS metastasis from uterine cancer: A retrospective analysis and literature review. Gynecol Oncol. 2007;107:79-85.
Downs LS Jr, Judson PL, Argenta PA, Ghebre R, Geller MA, Bliss RL, Boente MP, Nahhas WA, Abu-Ghazaleh SZ, Chen MD, Carson LF. A prospective randomized trial of Thalidomide with Topotecan compared to Topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 2008;112;331-339.
Argenta PA, Ormsby RR, Downs LS Jr, Judson PL, Ghebre R, Carson LF. Routine pelvic examination during front line chemotherapy for ovarian cancer: Is there a role? J Reprod Med. 2008;53:3-7.
Argenta PA, Thomas SG, Judson PL, Downs LS Jr, Geller MA, Carson LF, Jonson AL, Ghebre R. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol. 2009;113:205-209.
Geller MA, Ivy J, Dusenbery KE, Ghebre R, Vogel RI, Argenta PA. A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high risk endometrial carcinoma. Gynecol Oncol. 2010; 118:19-23.
Geller MA, Downs LS, Judson PL, Ghebre R, Argenta PA, Carson LF, Jonson AL, Godfrey K, Isaksson Vogel R, Petzel Sv. Learning about ovarian cancer at the time of diagnosis: Video versus usual care. Gynecol Oncol. 2010;119:370-375.
Geller MA, Cooley S, Argenta PA, Downs LS , Carson LF, Judson PL, Ghebre R, Weigel B, Panoskaltsis-Mortari A, Curtsinger J, Miller JS. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother. 2010; 59:1877-1884.
Subramanian IV, Devineni S, Ghebre R, Ghosh G, Joshi HP, Jing Y, Truskinovsky AM, Ramakrishnan S. AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer. Gene Ther. 2011;18:145-154.
Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13:98-107.
Downs LS Jr, Chura JC, Argenta PA, Judson PL, Ghebre R, Geller MA, Carson LF. Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: A phase II trial. Gynecol Oncol. 2011;120:265-269.
Geller MA, Ivy JJ, Ghebre R, Downs LS Jr, Judson PL, Carson LF, Jonson AL, Dusenbery K, Vogel RI, Boente MP, Argenta PA. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol. 2011;121:112-117.
Ghebre RG, Posthuma R, Vogel RI, Geller MA, Carson LF. Effect of age and comorbidity on the treatment and survival of elderly patients with vulvar cancer. Gynecol Oncol. 2011;121:595-599.
Judson PL, Dickson EL, Argenta PA, Xiong Y, Geller MA, Carson LF, Ghebre R, Jonson AL, Downs LS Jr. A prospective, randomized trial of integrative medicine for women with ovarian cancer. Gynecol Oncol. 2011;123:346-350.
